The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gumenetskaia Iu.V.

FGBU "Meditsinskiĭ radiologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Obninsk

Teleradiotherapy in the treatment of muscle invasive bladder cancer

Authors:

Gumenetskaia Iu.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(3): 77‑81

Views: 1608

Downloaded: 22

Download PDF (RU)
Contact the author
Table of contents

TELERADIOTHERAPY IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER
TELERADIOTHERAPY IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER

To cite this article:

Gumenetskaia IuV. Teleradiotherapy in the treatment of muscle invasive bladder cancer. P.A. Herzen Journal of Oncology. 2012;1(3):77‑81. (In Russ.)

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Close metadata
Recommended articles:
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35

The review gives the data available in the literature on the use of teleradiotherapy in patients with muscle invasive bladder cancer. The variants of nontraditional dose fractionation during radical and palliative radiation therapy are considered.

Keywords:

bladder cancer
teleradiotherapy
nontraditional fractionation regimens

Authors:

Gumenetskaia Iu.V.

FGBU "Meditsinskiĭ radiologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Obninsk

List of references:

  1. Chissov V.I., Starinskii V.V., Petrova G.V., red. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2010 godu. M.: FGU "MNIOI im. P.A. Gertsena Minzdravsotsrazvitiya Rossii"; 2011. 188 s.
  2. Kanaev S.V. Rol' luchevoi terapii v lechenii raka mochevogo puzyrya. V kn.: Vorob'ev A.V., Tyulyandin S.A., Moiseenko V.M., red. Prakticheskaya onkourologiya: izbrannye lektsii. SPb.: Tsentr TOMM; 2008: 163-76.
  3. Soen J.J., Zietman A.L., Kaufman D.S., Heney N.M., Althausen A.F., Shipley W.U. Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach. In: Lerner S.P., Schoenberg M.P., Sternberg C.N., eds. Treatment and management of bladder cancer. London: Informa UK Ltd.; 2008: 167-74.
  4. Milosevic M.F., Bristow R., Gospodarowicz M.K. Optimal radiotherapy for bladder cancer. In: Lerner S.P., Schoenberg M.P., Sternberg C.N., eds. Treatment and management of bladder cancer. London: Informa UK Ltd.; 2008: 151-65.
  5. Petrovich Z., Stein J.P., Jozsef G., Formenti S.C. Bladder. In: Perez C.A., Brady L.W., Halperin E.D., ed. Principles and practice of radiation oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 1412-38.
  6. Sengelov L., von der Maase H. Radiotherapy in bladder cancer. Radiother. Oncol. 1999; 52 (1): 1-14.
  7. Tkachev S.I., Figurin K.M., Medvedev S.V. Luchevaya terapiya bol'nykh rakom mochevogo puzyrya. Onkourologiya. 2006; 3: 5-11.
  8. Gospodarowicz M.K. Radiotherapy and organ preservation in bladder cancer: are we ignoring the evidence? J. Clin. Oncol. 2002; 20 (14): 3048-50.
  9. Joynson C.P., Sundar S., Symonds P. Anaemia is associated with poor overall survival but not with inferior local control in patients with muscle invasive bladder carcinoma treated by radical external beam radiotherapy. A retrospective study. Clin. Oncol. 2006; 18 (10): 728-74.
  10. Munro N.P., Sundaram S.K., Weston P.M., Fairley L., Harrison S.C., Forman D. et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in yorkshire, UK. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77 (1): 119-24.
  11. Pollack A., Zagars G.K., Swanson D.A. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30 (2): 267-77.
  12. Tonoli S., Bertoni F., De Stefani A., Vitali E., De Tomasi D., Caraffini B. et al. Radical radiotherapy for bladder cancer: retrospective analysis of a series of 459 patients treated in an Italian institution. Clin. Oncol. 2006; 18 (1): 52-9.
  13. Mardynskii Yu.S. Rak mochevogo puzyrya. V kn.: Kiseleva E.S., red. Luchevaya terapiya zlokachestvennykh opukholei. M.: Meditsina; 1996: 338-50.
  14. Foster W., Lee B., Speight J.L. Bladder cancer. In: Hansen E.K., Roach M. III., eds. Handbook of evidence-based radiation oncology. 2nd ed. New York, USA: Springer; 2010: 419-29.
  15. Abazeed M.E., Efstathiou J.A., Heney N.M., Niemierko A., Kaufman D.S., Shipley W.U. Bladder preservation strategies for invasive bladder cancer. In: Scardino P.T., Linehan W.M., Zelefsky M.J., Vogelzang N.J., eds. Comprehensive textbook of genitourinary oncology. Philadelphia: Wolters Kluwer; 2011: 451-69.
  16. Akimov A.A., Il'in N.V. Rol' fraktsionirovaniya dozy v povyshenii effektivnosti luchevoi terapii opukholei. SPb.: Berserk; 2005. 29 s.
  17. Boiko A.V., Chernichenko A.V., Dar'yalova S.L., Meshcheryakova I.A., Ter-Arutyunyants S.A. Netraditsionnoe fraktsionirovanie dozy. V kn.: Materialy V Rossiiskoi onkologicheskoi konferentsii. 27-29 noyabrya 2001 g., Moskva. M.; 2001: 120-2.
  18. Boiko A.V., Dar'yalova S.L., Chernichenko A.V., Bocharova I.A. Luchevaya terapiya. V kn.: Chissov V.I., Davydov M.I., red. Onkologiya. Natsional'noe rukovodstvo. M.: GEOTAR-Media; 2008: 394-437.
  19. Beck-Bornholdt H.P., Dubben H.H., Liertz-Petersen C., Willers H. Hyperfractionation: where do we stand? Radiother. Oncol. 1997; 43 (1): 1-21.
  20. Horwich A., Dearnaley D., Huddart R., Graham J., Bessell E., Mason M. et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother. Oncol. 2005; 75 (1): 34-43.
  21. Yavus A.A., Yavus M.N., Ozgur G.K., Colak F., Ozyavuz R., Cimsitoqlu E. et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56 (3): 734-45.
  22. Moonen L., van der Voet H., Horenblas S., Bartelink H. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int. J. Radiat. Oncol. Biol. Phys. 1997; 37 (3): 537-42.
  23. Ang K.K. Fractionation effects in slinical practice. In: Leibel S.A., Phillips T.L., eds. Textbook of radiation oncology. Philadelphia: W.B. Saunders Company; 1998; 26-41.
  24. Edsmyr F., Andersson L., Esposti P.L., Littbrand B., Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother. Oncol. 1985; 4 (3): 197-203.
  25. Naslund I., Nilsson B., Littbrand B. Hyperfractionated radiotherapy of bladder cancer. Acta. Oncol. 1994; 33 (4): 397-402.
  26. Goldobenko G.V., Matveev B.P., Shipilov V.I., Klimakov B.D., Tkachev S.I. Luchevoe lechenie raka mochevogo puzyrya pri razlichnykh rezhimakh fraktsionirovaniya. Meditsinskaya radiologiya. 1991; 5: 14-6.
  27. Bolotina L.V., Rusakov I.G. Invazivnyi rak mochevogo puzyrya: sovremennye podkhody k lecheniyu. Rossiiskii onkologicheskii zhurnal. 2007; 6: 47-51.
  28. Matveev V.B., Volkova M.I. Gemtsitabin (Tsitogem) v lechenii rasprostranennogo perekhodno-kletochnogo raka mochevogo puzyrya. Onkourologiya. 2008; 4: 74-9.
  29. Rusakov I.G., Golovashchenko M.P. Khimioterapiya myshechno-invazivnogo raka mochevogo puzyrya. Onkourologiya. 2011; 3: 90-4.
  30. Housset M., Durdux C., Thariat J., Dufour B. Chemoradiation in bladder cancer. Bull. Cancer. 2010; 97 (suppl.): 19-25.
  31. Muller A.C., Diestelhorst A., Kuhnt T., Fornara P., Scholz H.J., Dunst J. et al. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther. Oncol. 2007; 183 (4): 177-83.
  32. Oh K.S., Soto D.E., Smith D.C., Montie J.E., Lee C.T., Sandler H.M. Combined-Modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int. J. Radiat. Oncol. Biol. Phys. 2009; 74 (2): 511-7.
  33. Matveev B.P., Figurin K.M., Karyakin O.B. Rak mochevogo puzyrya. M.: Verdana; 2001. 243 s.
  34. Rusakov I.G., Teplov A.A., Perepechin D.V, Ul'yanov R.V. Rak mochevogo puzyrya. V kn.: Chissov V.I., Davydov M.I., red. Onkologiya. Natsional'noe rukovodstvo. M.: GEOTAR-Media; 2008: 777-88.
  35. Sitdykova M.E., Zubkov A.Yu., Nuriev I.R. Rezul'taty organosberegayushchego operativnogo lecheniya novoobrazovanii mochevogo puzyrya. V kn.: Materialy VI kongressa Rossiiskogo obshchestva onkourologov. 5-7 oktyabrya 2011 g., Moskva. M.; 2011: 193-4.
  36. Solsona E., Iborra I., Collado A., Rubio-Briones J., Casanova J., Calatrava A. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J. Urol. 2010; 184 (2): 475-80.
  37. Langsenlehner T., Doller C., Quehenberger F., Stranzl-Lawatsch H., Langsenlehner U., Pummer K. et al. Treatment results of radiation therapy for muscle-invasive bladder cancer. Strahlenther. Oncol. 2010; 186 (4): 203-9.
  38. Tester W., Porter A., Asbell S., Coughlin C., Heaney J., Krall J. et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int. J. Radiat. Oncol. Biol. Phys. 1993; 25 (5): 783-90.
  39. Tester W., Caplan R., Heaney J., Venner P., Whittington R., Byhardt R. et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J. Clin Oncol. 1996; 14 (1): 119-26.
  40. Shipley W.U., Winter K.A., Kaufman D.S., Lee W.R., Heney N.M., Tester W.R. et al. Phase III trial of neoajuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol. 1998; 16 (11): 3576-83.
  41. Housset M., Dufour B., Maulard-Durdux C., Chretven Y., Mejean A. Concominant fluorouracil (5FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc. Am. Soc. Clin. Oncol. 1997; 16: 319-25 (abstr. 1139).
  42. Rodel C., Grabenbauer G.G., Kuhn R., Papadopoulos T., Dunst J., Meyer M. et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 2002; 20 (14): 3061-71.
  43. Shipley W.U., Kaufman D.S., Zehr E., Heney N.M., Lane S.C., Thakral H.K. et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology. 2002; 60 (1): 62-7.
  44. Hagan M.P., Winter K.A., Kaufman D.S., Wajsman Z., Zietman A.L., Heney N.M. et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57 (3): 665-72.
  45. Kaufman D.S., Winter K.A., Shipley W.U., Heney N.M., Wallace H.J., Toonkel L.M. et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009; 73 (4): 833-7.
  46. Efstathiou J.A., Spiegel D.Y., Shipley W.U., Heney N.M., Kaufman D.S., Niemierco A. et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur. Urol. 2012; 61 (4): 705-11.
  47. Karyakin O.B. Organosokhrannaya taktika pri invazivnom rake mochevogo puzyrya: "za" i "protiv". V kn.: Vorob'ev A.V., Tyulyandin S.A., Moiseenko V.M., red. Prakticheskaya onkourologiya: izbrannye lektsii. SPb.: Tsentr TOMM; 2008: 177-82.
  48. Shoudhury A., Cowan R. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. Br. J. Urol. Int. 2011; 108 (9): E313.
  49. Kotwal S., Choudhury A., Johnston C. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int. J. Radiat. Oncol. Biol. Phys. 2008; 70 (2): 456-63.
  50. Krause F.S., Walter B., Ott O.J., Haberle L., Weiss C., Rodel C. et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res. 2011; 31 (3): 985-90.
  51. Ott O.J., Rodel C., Weiss C., Wittlinger M., St Krause F., Dunst J. et al. Radiochemotherapy for bladder cancer. Clin. Oncol. 2009; 21 (7): 557-65.
  52. Rene N.J., Cury F.B., Souhami L. Conservative treatment of invasive bladder cancer. Curr. Oncol. 2009; 16 (4): 36-47.
  53. Rodel C., Weiss C., Sauer R.J. Trimodality treatment and selective organ preservation for bladder cancer. J. Clin. Oncol. 2006; 24 (35): 5536-44.
  54. Yafi F.A., Cury F.L., Kassouf W. Organ-sparing strategies in the management of invasive bladder cancer. Expert Rev. Anticancer Ther. 2009; 9 (12): 1765-75.
  55. Yafi F.A., Aprikian A.G., Chin J.L., Fradet Y., Izawa J., Estey E. et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. Br. J. Urol. Int. 2011; 108 (4): 539-45.
  56. Zapatero A., Martin de Vidales C., Arellano R., Bocardo G., Perez M., Rios P. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol. Oncol. 2010; 28 (4): 368-74.
  57. Efstathiou J.A., Bae K., Shipley W.U. Kaufman D.S., Hagan M.P., Heney N.M. et al. Late pelvis toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J. Clin. Oncol. 2009; 27 (25): 4051-61.
  58. Lagrange J.L., Bascoul-Mollevi C., Geoffrois L., Beckendorf V., Ferrero J.M., Joly F. et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int. J. Radiat. Oncol. Biol. Phys. 2011; 79 (1): 172-8.
  59. Lutz S.T., Chow E.L., Hartsell W.F., Konski A.A. A review of hypofractionated palliative radiotherapy. Cancer. 2007; 109 (8): 1462-70.
  60. Duchesne G.M., Bolger J.J., Griffiths G.O., Roberts J.T., Graham J.D., Hoskin P.J. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int. J. Radiat. Oncol. Biol. Phys. 2000; 47: 379-88.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.